Thanks for signing up for DividendStocks.com! It's the daily newsletter built for dividend and income investors. Before we can begin sending your daily updates, there’s one quick step left. Please confirm your subscription using the link below so our emails reach your inbox. Click Here to Confirm Your Subscription to DividendStocks.com Here’s a small glimpse of what you’ll get access to: Dividend Stock Ideas — Each newsletter features dividend stocks with high yields, sustainable payouts, and strong growth potential. Ex-Dividend Stocks — Want to capture upcoming dividend payouts? Find out which stocks are going ex-dividend this week. Market News and Events — Stay in the loop on the latest developments impacting popular dividend names like AT&T, Exxon Mobil, IBM, Procter & Gamble, and Verizon. Bonus: As a thank-you for confirming, you’ll also receive a free PDF copy of Automatic Income, our popular guide to building wealth through dividend investing. Let’s get your dividend journey started! Discover Top Income-Generating Stocks Here See you in your inbox soon,
The DividendStocks.com Team P.S. Don’t miss out click here to verify your subscription and secure your daily dividend insights and your free investing guide!
More Reading from MarketBeat Why 2 Small Biotechs May Hold the Key to New Cancer TreatmentsBy Nathan Reiff. Publication Date: 3/12/2026. 
Key Points - Iovance and ImmunityBio each have a leading oncology product that has helped to massively boost sales and share prices in recent quarters.
- Despite major gains in recent trading, IOVA and IBRX shares still have at least 70% in upside potential going forward, according to analysts.
- Profitability remains a concern for both companies, even as sales of their top cancer drugs have surged.
- Special Report: Elon's "Hidden" Company
Cancer remains one of the greatest medical challenges for biotechnology firms, even as the oncology medicine market is expected to surge to $366 billion over the next eight years. Companies often take a niche approach, developing medicines aimed at specific types of cancer with targeted mechanisms. Several promising treatments have shown strong potential—and with that comes the possibility of significant sales. Two small biotech companies are seeing strong share-price momentum thanks to their leading oncology medicines. Besides offering therapeutic potential, these drugs could help the firms move beyond penny-stock (or otherwise unstable) status toward long-term profitability. That said, challenges remain; these are typical biotech investments—high-risk ventures that could also offer outsized rewards for investors willing to take a chance. Iovance's Powerful Cancer Drug Is Growing, But Production Challenges Are a Hurdle Iovance Biotherapeutics Inc. (NASDAQ: IOVA) defied market trends in early March, surging nearly 37% in a week when the S&P 500 dipped about 1%. That added to IOVA's year-to-date (YTD) performance, which has seen shares more than double. Still, with a consensus price target of $8.88, Wall Street appears to expect more—that target implies roughly 71% upside from current levels. The main catalyst for Iovance's price movement is its lead product, Amtagvi, a T-cell immunotherapy for certain types of melanoma. Amtagvi has been approved in the United States since 2024 and is gaining momentum in sales, with additional approvals likely in the E.U., U.K., and elsewhere. When administered with Proleukin, the company's IL-2 immunotherapy, management believes Amtagvi could reach more than $1 billion in U.S. sales at peak. Amtagvi's potential may extend beyond melanoma: the drug received Fast Track Designation from the FDA for the treatment of non-small cell lung cancer and is being evaluated for other indications. Some of Iovance's outperformance this year can also be attributed to its Q4 2025 earnings report, issued in late February, in which the company posted a smaller-than-expected loss per share and $5 million in revenue. For the full year, revenue climbed roughly 30% year-over-year (YOY). Iovance is still a penny stock and a relatively small (about $2 billion market-cap) biotech, and despite the strong rally this year, analysts remain cautious—about half of the roughly dozen ratings are Hold or Sell. Risks are high: beyond the typical challenges small biotechs face, Iovance's manufacturing process for Amtagvi leaves it vulnerable. The therapy is personalized, expensive, and complex to produce, which could limit Iovance's ability to achieve profitability even as demand grows. Massive Sales Growth for ImmunityBio's Bladder Cancer Drug While ImmunityBio Inc. (NASDAQ: IBRX) fell about 20% in March, its YTD performance dwarfs Iovance's. IBRX shares are up nearly 300% in 2026 alone, and this may be just the beginning. Analysts have set a price target of $13.60, roughly 70% higher than the stock's current price even after the recent surge. ImmunityBio's lead product and primary growth driver is Anktiva, a treatment for certain types of bladder cancer. In February, shares jumped after the EU regulator granted the drug conditional marketing authorization—the latest in a series of approvals worldwide. Anktiva is already driving the firm's revenue performance, producing $113 million in sales last year, roughly a 700% YOY increase. Like Amtagvi, Anktiva may have potential across additional cancer indications, and ImmunityBio is actively exploring those possibilities. Despite the recent run-up, IBRX remains speculative and risky. IBRX reported a sizable full-year net loss of $351 million for 2025 as R&D expenses continue to climb. Analysts appear slightly more bullish on ImmunityBio than on Iovance—six of seven covering the stock rate it a Buy or equivalent. | 
